<DOC>
	<DOCNO>NCT00413114</DOCNO>
	<brief_summary>Defects apoptotic process lead onset cancer allow cell grow unchecked oncogeneic signal present . Obatoclax design restore apoptosis inhibition Bcl-2 family protein , thereby reinstate natural process cell death often inhibited cancer cell . This multi-center , open-label , Phase II study obatoclax administer 2-week cycle patient previously-untreated Myelodysplastic Syndromes anemia and/or thrombocytopenia . Treatment may administer outpatient basis . No investigational commercial agent therapy describe herein may administer intent treat patient 's malignancy . Supportive care measure include direct control symptom result Myelodysplastic Syndromes allow</brief_summary>
	<brief_title>Safety Efficacy Obatoclax Mesylate ( GX15-070MS ) Treatment Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Pathological confirmation Myelodysplastic Syndromes ( MDS ) Patients must prior systemic therapy Must normal organ function Must ability understand willingness sign write informed consent form Must result prior chemotherapy and/or radiotherapy another malignancy No agent therapy administer intent treat Uncontrolled , intercurrent illness Pregnant woman woman breast feed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>